AcelRx Pharmaceuticals, Inc. (NASDAQ:ACRX) had its price objective decreased by analysts at Royal Bank Of Canada from $6.00 to $5.00 in a research note issued on Friday. The brokerage currently has an “outperform” rating on the specialty pharmaceutical company’s stock. Royal Bank Of Canada’s target price indicates a potential upside of 132.56% from the company’s previous close.

ACRX has been the subject of a number of other reports. Cowen and Company reiterated a “hold” rating on shares of AcelRx Pharmaceuticals in a report on Tuesday, August 1st. Stifel Nicolaus upgraded AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Wednesday, August 9th. ValuEngine upgraded AcelRx Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, September 26th. Piper Jaffray Companies set a $3.00 target price on AcelRx Pharmaceuticals and gave the stock a “hold” rating in a report on Tuesday, July 25th. Finally, Zacks Investment Research upgraded AcelRx Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Friday, August 4th. One research analyst has rated the stock with a sell rating, four have assigned a hold rating and four have assigned a buy rating to the company. AcelRx Pharmaceuticals currently has a consensus rating of “Hold” and an average target price of $7.83.

Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) opened at 2.15 on Friday. The stock has a 50 day moving average price of $3.80 and a 200-day moving average price of $2.97. The company’s market capitalization is $97.57 million. AcelRx Pharmaceuticals has a 52 week low of $1.95 and a 52 week high of $5.75.

AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its earnings results on Tuesday, August 1st. The specialty pharmaceutical company reported ($0.29) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.28) by ($0.01). The business had revenue of $2.66 million during the quarter, compared to analyst estimates of $2.63 million. Equities research analysts expect that AcelRx Pharmaceuticals will post ($1.13) EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was originally posted by American Banking News and is the property of of American Banking News. If you are reading this article on another domain, it was stolen and republished in violation of United States and international copyright and trademark law. The original version of this article can be read at https://www.americanbankingnews.com/2017/10/13/royal-bank-of-canada-trims-acelrx-pharmaceuticals-inc-acrx-target-price-to-5-00.html.

In other news, insider Pamela P. Palmer acquired 10,000 shares of the firm’s stock in a transaction dated Tuesday, August 22nd. The stock was purchased at an average price of $2.95 per share, for a total transaction of $29,500.00. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Vincent J. Angotti acquired 15,000 shares of the firm’s stock in a transaction dated Thursday, August 24th. The shares were purchased at an average price of $3.00 per share, with a total value of $45,000.00. Following the acquisition, the chief executive officer now owns 15,000 shares of the company’s stock, valued at $45,000. The disclosure for this purchase can be found here. In the last 90 days, insiders have bought 37,000 shares of company stock valued at $112,280. Corporate insiders own 28.10% of the company’s stock.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in ACRX. Wells Fargo & Company MN increased its holdings in shares of AcelRx Pharmaceuticals by 196.3% during the third quarter. Wells Fargo & Company MN now owns 28,403 shares of the specialty pharmaceutical company’s stock valued at $111,000 after acquiring an additional 18,818 shares in the last quarter. ING Groep NV increased its holdings in shares of AcelRx Pharmaceuticals by 200.0% during the first quarter. ING Groep NV now owns 39,000 shares of the specialty pharmaceutical company’s stock valued at $123,000 after acquiring an additional 26,000 shares in the last quarter. Acadian Asset Management LLC increased its holdings in shares of AcelRx Pharmaceuticals by 326.1% during the first quarter. Acadian Asset Management LLC now owns 41,927 shares of the specialty pharmaceutical company’s stock valued at $132,000 after acquiring an additional 32,087 shares in the last quarter. Schwab Charles Investment Management Inc. bought a new stake in shares of AcelRx Pharmaceuticals during the second quarter valued at approximately $155,000. Finally, Teachers Advisors LLC increased its holdings in shares of AcelRx Pharmaceuticals by 14.6% during the fourth quarter. Teachers Advisors LLC now owns 66,715 shares of the specialty pharmaceutical company’s stock valued at $173,000 after acquiring an additional 8,475 shares in the last quarter. Hedge funds and other institutional investors own 23.32% of the company’s stock.

AcelRx Pharmaceuticals Company Profile

AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.

Analyst Recommendations for AcelRx Pharmaceuticals (NASDAQ:ACRX)

Receive News & Ratings for AcelRx Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.